title: Do 18F-FDG PET/CT findings have a relationship with histopathological and immunohistochemical factors of breast cancer in men?
abstract: OBJECTIVE
  We aimed to investigate the relationship between histopathological and immunohistochemical features of male breast cancer (MBC) and comprehensive fluorine-18-fluorodeoxyglucose (F-FDG) PET/computed tomography (CT) parameters.
  
  
  METHODS
  Fifteen male patients with newly diagnosed breast cancer who underwent F-FDG PET/CT were included in the study. Maximum and average standardized uptake value (SUVmax and SUVavg), metabolic total volume, and total lesion glycolysis (TLG) were compared with the histopathological and immunohistochemical findings of patients. In addition, metabolic tumor-node-metastases (TNM) staging was performed following the determination of metastatic axillary lymph nodes and tumor size by F-FDG PET/CT and verified by histopathological evaluation.
  
  
  RESULTS
  There were no significant differences between all groups classified on the basis of histopathological and immunohistochemical parameters for SUVmax, SUVavg, TLG, and metabolic total volume. The only difference was found in patients with distant metastases and stage IV. SUVmax, SUVavg, and TLG were higher in patients with distant metastases compared with patients without distant metastases (P: 0.005, 0.011, and 0.042, respectively). Strong correlations were found between metabolic TNM staging and histopathological TNM staging (for T stage; r: 0.590, P: 0.021, N stage; r: 0.694, P: 0.002, TNM stage; r: 0.835, P: 0.002). In addition, no differences were found with any metabolic F-FDG PET/CT parameters in survival.
  
  
  CONCLUSIONS
  Although no correlation was found between metabolic parameters and groups categorized on the basis of histopathological or immunohistochemical features, F-FDG PET/CT is a reliable imaging modality to determine tumor size, axillary lymph node involvement, and metabolic TNM staging of MBC. In addition, none of those metabolic F-FDG PET/CT parameters predicted survival in MBC.
authors.affiliation: Department of aNuclear Medicine bSurgery cPathology, Cerrahpaşa Faculty of Medicine dNuclear Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
authors.forename: Betül
authors.initials: B
authors.lastname: Vatankulu
authors.forename: Göknur
authors.initials: G
authors.lastname: Işik
authors.forename: Pinar
authors.initials: P
authors.lastname: Kocael
authors.forename: Serkan
authors.initials: S
authors.lastname: Kuyumcu
authors.forename: Şennur
authors.initials: Ş
authors.lastname: Ilvan
authors.forename: Sait
authors.initials: S
authors.lastname: Sağer
authors.forename: Metin
authors.initials: M
authors.lastname: Halaç
authors.forename: Cüneyt
authors.initials: C
authors.lastname: Türkmen
authors.forename: Kerim
authors.initials: K
authors.lastname: Sönmezoğlu
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018567:Breast Neoplasms, Male / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D000072078:Positron Emission Tomography Computed Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D012189:Retrospective Studies
chemical_list: D005462:Fluorine Radioisotopes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18